Welcome to our dedicated page for Satellos Bioscience news (Ticker: MSLE), a resource for investors and traders seeking the latest updates and insights on Satellos Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Satellos Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Satellos Bioscience's position in the market.
Satellos (NASDAQ: MSLE) will present two oral talks and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, March 8-11 in Orlando, Florida.
Oral sessions report Phase 1a/b SAT-3247 data in healthy volunteers and Duchenne muscular dystrophy, plus preclinical SAT-3247 FSHD mouse-model data; three posters cover Phase 1a/b, a Phase 2 TRAILHEAD study, and a regenerative index analysis in DMD.
Satellos (NASDAQ: MSLE) will host a virtual key opinion leader event on Feb. 24, 2026 at 3:30 p.m. ET to discuss Duchenne muscular dystrophy (DMD) and its treatment landscape.
The session features Dr. Kevin M. Flanigan and management, reviews completed Phase 1a/b data in healthy volunteers and adults with DMD, outlines the open-label TRAILHEAD adult study, and provides updates on BASECAMP, an ongoing Phase 2 pediatric study of oral SAT-3247 targeting AAK1 to support muscle repair.
Satellos Bioscience (Nasdaq: MSLE) announced management will present at multiple investor conferences in late February and March 2026, including Oppenheimer, TD Cowen and Leerink Partners.
Presentations are scheduled as virtual and in-person sessions; live webcasts will be available on the company’s Events and Presentations page, and leadership will be available for one-on-one investor meetings.
Satellos (TSX: MSCL, OTCQB: MSCLF; ticker MSLE) announced dosing of the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy.
The proof-of-concept trial will enroll 51 ambulatory children aged 7–9, with primary endpoints of safety, tolerability and muscle force; secondary endpoints include muscle quality, function and regeneration. Satellos plans 25 sites across the United States, Europe, U.K., Australia, Canada and Serbia; the study is actively enrolling.
Satellos (Nasdaq: MSLE) management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York on Feb. 12, 2026 at 10:00 a.m. ET. The session will be streamed via live webcast and a replay will be posted on the company investor site.
Satellos leadership will also hold one-on-one investor meetings during the conference; interested investors may contact their Guggenheim representative or email ir@satellos.com to schedule.
Satellos (Nasdaq: MSLE) completed an underwritten public offering raising approximately US$57.2 million gross by issuing 5,168,019 common shares (including 712,574 underwriter option shares) and 495,049 pre-funded warrants.
Shares sold at US$10.10 and pre-funded warrants at US$10.09999. Net proceeds are intended to fund R&D, working capital and to advance SAT-3247 through Phase 2 to Phase 3 trials and other discovery or pre-clinical programs.
Satellos (TSX: MSCL; Nasdaq: MSLE) priced a public offering expected to raise ~US$50.0 million by selling 4,455,445 common shares and 495,049 pre-funded warrants at US$10.10 per share (pre-funded warrants at US$10.09999).
Closing is expected Feb 9, 2026, subject to TSX and Nasdaq approvals; net proceeds will fund R&D including advancement of SAT-3247 and general corporate purposes. A 30-day underwriter option could add 742,574 shares.